BACKGROUND AND OBJECTIVES: The choice of induction agent in the elderly kidney transplant recipient is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The risks of rejection at 1 year, functional graft loss, and death by induction agent (IL2 receptor antibodies [IL2RA], alemtuzumab, and rabbit antithymocyte globulin [rATG]) were compared among five groups of elderly (≥60 years) deceased-donor kidney transplant recipients on the basis of recipient risk and donor risk using United Network of Organ Sharing data from 2003 to 2008. RESULTS: In high-risk recipients with high-risk donors there was a higher risk of rejection and functional graft loss with IL2RA versus rATG. Among low-risk recipients with low-risk donors there was no difference in outcomes between IL2RA and rATG. In the two groups in which donor or recipient was high risk, there was a higher risk of rejection but not functional graft loss with IL2RA. Among low-risk recipients with high-risk donors, there was a trend toward a higher risk of death with IL2RA. CONCLUSIONS: rATG may be preferable in high-risk recipients with high-risk donors and possibly low-risk recipients with high-risk donors. In the remaining groups, although rATG is associated with a lower risk of acute rejection, long-term outcomes do not appear to differ. Prospective comparison of these agents in an elderly cohort is warranted to compare the efficacy and adverse consequences of these agents to refine the use of induction immunosuppressive therapy in the elderly population.
BACKGROUND AND OBJECTIVES: The choice of induction agent in the elderly kidney transplant recipient is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The risks of rejection at 1 year, functional graft loss, and death by induction agent (IL2 receptor antibodies [IL2RA], alemtuzumab, and rabbit antithymocyte globulin [rATG]) were compared among five groups of elderly (≥60 years) deceased-donor kidney transplant recipients on the basis of recipient risk and donor risk using United Network of Organ Sharing data from 2003 to 2008. RESULTS: In high-risk recipients with high-risk donors there was a higher risk of rejection and functional graft loss with IL2RA versus rATG. Among low-risk recipients with low-risk donors there was no difference in outcomes between IL2RA and rATG. In the two groups in which donor or recipient was high risk, there was a higher risk of rejection but not functional graft loss with IL2RA. Among low-risk recipients with high-risk donors, there was a trend toward a higher risk of death with IL2RA. CONCLUSIONS: rATG may be preferable in high-risk recipients with high-risk donors and possibly low-risk recipients with high-risk donors. In the remaining groups, although rATG is associated with a lower risk of acute rejection, long-term outcomes do not appear to differ. Prospective comparison of these agents in an elderly cohort is warranted to compare the efficacy and adverse consequences of these agents to refine the use of induction immunosuppressive therapy in the elderly population.
Authors: H U Meier-Kriesche; A Ojo; J Hanson; D Cibrik; K Lake; L Y Agodoa; A Leichtman; B Kaplan Journal: Transplantation Date: 2000-03-15 Impact factor: 4.939
Authors: Gabriel M Danovitch; David J Cohen; Matthew R Weir; Peter G Stock; William M Bennett; Laura L Christensen; Randall S Sung Journal: Am J Transplant Date: 2005-04 Impact factor: 8.086
Authors: Paulo N A Martins; Johann Pratschke; Andreas Pascher; Lutz Fritsche; Ulrich Frei; Peter Neuhaus; Stefan G Tullius Journal: Transplantation Date: 2005-01-27 Impact factor: 4.939
Authors: Alan C Farney; William Doares; Jeffrey Rogers; Rajinder Singh; Erica Hartmann; Lois Hart; Elizabeth Ashcraft; Amber Reeves-Daniels; Michael Gautreaux; Samy S Iskandar; Phillip Moore; Patricia L Adams; Robert J Stratta Journal: Transplantation Date: 2009-09-27 Impact factor: 4.939
Authors: Christian Noël; Daniel Abramowicz; Dominique Durand; Georges Mourad; Philippe Lang; Michèle Kessler; Bernard Charpentier; Guy Touchard; François Berthoux; Pierre Merville; Nacera Ouali; Jean-Paul Squifflet; François Bayle; Karl Martin Wissing; Marc Hazzan Journal: J Am Soc Nephrol Date: 2009-05-21 Impact factor: 10.121
Authors: U Frei; J Noeldeke; V Machold-Fabrizii; H Arbogast; R Margreiter; L Fricke; A Voiculescu; V Kliem; H Ebel; U Albert; K Lopau; P Schnuelle; B Nonnast-Daniel; F Pietruck; R Offermann; G Persijn; C Bernasconi Journal: Am J Transplant Date: 2007-10-31 Impact factor: 8.086
Authors: K Welzl; B Weinberger; A Kronbichler; G Sturm; G Kern; G Mayer; B Grubeck-Loebenstein; C Koppelstaetter Journal: Clin Exp Immunol Date: 2014-04 Impact factor: 4.330
Authors: D A Axelrod; A S Naik; M A Schnitzler; D L Segev; V R Dharnidharka; D C Brennan; S Bae; J Chen; A Massie; K L Lentine Journal: Am J Transplant Date: 2016-03-31 Impact factor: 8.086
Authors: María José Pérez-Sáez; Núria Montero; Dolores Redondo-Pachón; Marta Crespo; Julio Pascual Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: Frank P Hurst; Maria Altieri; Robert Nee; Lawrence Y Agodoa; Kevin C Abbott; Rahul M Jindal Journal: Am J Nephrol Date: 2011-11-18 Impact factor: 3.754
Authors: Neel Koyawala; Jeffrey H Silber; Paul R Rosenbaum; Wei Wang; Alexander S Hill; Joseph G Reiter; Bijan A Niknam; Orit Even-Shoshan; Roy D Bloom; Deirdre Sawinski; Susanna Nazarian; Jennifer Trofe-Clark; Mary Ann Lim; Jesse D Schold; Peter P Reese Journal: J Am Soc Nephrol Date: 2017-03-20 Impact factor: 10.121
Authors: Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius Journal: Transplantation Date: 2015-11 Impact factor: 4.939
Authors: Zahra Gharibi; Mehmet U S Ayvaci; Michael Hahsler; Tracy Giacoma; Robert S Gaston; Bekir Tanriover Journal: Transplantation Date: 2017-06 Impact factor: 4.939
Authors: M Abecassis; N D Bridges; C J Clancy; M A Dew; B Eldadah; M J Englesbe; M F Flessner; J C Frank; J Friedewald; J Gill; C Gries; J B Halter; E L Hartmann; W R Hazzard; F M Horne; J Hosenpud; P Jacobson; B L Kasiske; J Lake; R Loomba; P N Malani; T M Moore; A Murray; M-H Nguyen; N R Powe; P P Reese; H Reynolds; M D Samaniego; K E Schmader; D L Segev; A S Shah; L G Singer; J A Sosa; Z A Stewart; J C Tan; W W Williams; D W Zaas; K P High Journal: Am J Transplant Date: 2012-09-07 Impact factor: 8.086